J&J's JNJ-4804 Shows Superior Efficacy in Refractory IBD, Advancing to Phase 3
Event summary
- JNJ-4804 demonstrated higher clinical remission rates (50.8%) and endoscopic response rates (38.1%) in Crohn's disease vs. comparators.
- In ulcerative colitis, JNJ-4804 achieved 41.0% clinical remission vs. 11.5% for golimumab.
- Phase 3 trials (DUET ENCORE-CD and DUET ENCORE-UC) to begin following Phase 2b success.
- JNJ-4804 targets both IL-23 and TNF-α pathways, offering a novel co-antibody approach.
- Safety profile consistent with component monotherapies.
The big picture
J&J's JNJ-4804 represents a strategic push into combination therapy for refractory IBD, addressing a critical unmet need. The Phase 2b data positions JNJ-4804 as a potential market disruptor in a space dominated by monotherapies. Success in Phase 3 could expand J&J's leadership in inflammatory disease treatments.
What we're watching
- Clinical Validation
- Whether JNJ-4804 can sustain superior efficacy outcomes in Phase 3 trials.
- Regulatory Pathway
- The pace at which J&J advances JNJ-4804 toward potential approval.
- Market Positioning
- How JNJ-4804 differentiates against existing IBD therapies like TREMFYA.
Related topics